<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>Molecular Diversity Preservation International</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27713229</article-id><article-id pub-id-type="pmc">3978537</article-id><article-id pub-id-type="doi">10.3390/ph2030125</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-02-00125</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>
Combination Therapy with Olmesartan and Amlodipine in the Treatment of Hypertension
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Niemeijer</surname><given-names>Menco G.</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-02-00125">1</xref></contrib><contrib contrib-type="author"><name><surname>Cleophas</surname><given-names>Ton J.</given-names></name><xref ref-type="aff" rid="af2-pharmaceuticals-02-00125">2</xref><xref rid="c1-pharmaceuticals-02-00125" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-pharmaceuticals-02-00125"><label>1</label>Academic Medical Centre, Amsterdam, The Netherlands; Email: <email>m.g.niemeyer@gmail.com</email> (M.G.N.)</aff><aff id="af2-pharmaceuticals-02-00125"><label>2</label>Albert Schweitzer Hospital, Dordrecht, The Netherlands</aff><author-notes><corresp id="c1-pharmaceuticals-02-00125"><label>*</label> Author to whom correspondence should be addressed; Email: <email>tj.cleophas@gmail.com</email>; Tel.: +31 184 434222; Fax: +31 184 434340.</corresp></author-notes><pub-date pub-type="epub"><day>01</day><month>12</month><year>2009</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2009</year></pub-date><volume>2</volume><issue>3</issue><fpage>125</fpage><lpage>133</lpage><history><date date-type="received"><day>26</day><month>11</month><year>2009</year></date><date date-type="accepted"><day>30</day><month>11</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; 2009 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland.</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p><!--CREATIVE COMMONS-->This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>).</license-p></license></permissions><abstract><p><italic>Background:</italic> Combination therapy with antihypertensive agents utilises different mechanisms of action and may be responsible for a more effective decrease in blood pressure. <italic>Objective:</italic> To review the recently published trials on efficacy and safety of the combination therapy with olmesartan and amlodipine. <italic> Results:</italic> The double-blind American COACH (Combination of Olmesartan Medoxomil and Amlopdine Besylate in Controlling High Blood Pressure) study (2008) showed in 1,940 patients that after eight weeks of treatment the BP goals were most frequently achieved in the &#x02018;combination therapy group&#x02019;, with 56.3% (54.1&#x02013;58.5%) and 54.0% (51.8&#x02013;56.2%) of patients reaching adequate blood pressure of &#x0003c;140/90 mmHg with olmesartan/amlodipine 20/10 and 40/10 respectively. Combination therapy was generally well tolerated. The most common side effect was oedema [olmesartan 20 mg 9.9% (8.6&#x02013;11.3%), amlodipine 10 mg 36.8% (34.7&#x02013;39.0%), placebo 12.3% (10.9&#x02013;13.8%)]. The frequency of oedema was lower in the groups combining amlodipine 10 mg with olmesartan 10 mg (26.5%, 24.5&#x02013;28.5%), 20 mg (25.6%, 23.7&#x02013;27.6%) or 40 mg (23.5%, 21.6&#x02013;25.4%). In 2009 three double-blind controlled European studies including 500&#x02013;1,000 patients each and performed independently of one another have confirmed the above study, and have demonstrated similar efficacy-safety effects from the combination of olmesartan medoxomil with amlodipine, particularly for patients not achieving adequate blood pressure control with olmesartan monotherapy. <italic>Conclusions:</italic> Combinations of olmesartan and amlodipine were significantly more effective at reducing blood pressure and realising guideline blood pressure goals in patients with mild to severe hypertension than monotherapy (with a placebo component). Combination therapy is well tolerated and is associated with a lower incidence of side effects, such as oedema, compared to monotherapy with high amlodipine dosages (10 mg). </p></abstract><kwd-group><kwd>olmesartan</kwd><kwd>amlodipine</kwd><kwd>combination therapy</kwd><kwd>hypertension</kwd></kwd-group></article-meta></front><body><sec><title>1. Introduction</title><p>According to the most recent data from the National Health and Nutrition Examination Survey, the prevalence of (age adjusted) hypertension in the American population, estimated from 14,653 individuals, is 29.3% (28.6&#x02013;30.0%) (throughout the article 95% confidence intervals of point estimates are given) and is increasing [<xref rid="B1-pharmaceuticals-02-00125" ref-type="bibr">1</xref>]. This data corresponds to findings from studies undertaken in Western Europe [<xref rid="B2-pharmaceuticals-02-00125" ref-type="bibr">2</xref>]. Various studies have demonstrated that hypertension is clearly underdiagnosed and undertreated in both Europe and the United States (<xref ref-type="fig" rid="pharmaceuticals-02-00125-f001">Figure 1</xref>) [<xref rid="B2-pharmaceuticals-02-00125" ref-type="bibr">2</xref>]. </p><fig id="pharmaceuticals-02-00125-f001" position="float"><label>Figure 1</label><caption><p>International differences in control of hypertension (systolic blood pressure &#x0003c;140 mmHg and diastolic blood pressure &#x0003c;90 mmHg) and medication increase in patients with insufficiently controlled hypertension [<xref rid="B2-pharmaceuticals-02-00125" ref-type="bibr">2</xref>] (confidence intervals were not given in the report but were small given the large samples, e.g., 44.2&#x02013;47.7% and 13.8&#x02013;16.2% for France).</p></caption><graphic xlink:href="pharmaceuticals-02-00125-g001"/></fig><p>Classification of blood pressure in adults is determined in the &#x02018;JNC 7 report&#x02019; (<xref ref-type="table" rid="pharmaceuticals-02-00125-t001">Table 1</xref>) [<xref rid="B3-pharmaceuticals-02-00125" ref-type="bibr">3</xref>]. The following points are important in the treatment of hypertension:
<list list-type="simple"><list-item><label>&#x02014;</label><p>promoting a healthy lifestyle and identifying cardiovascular risk factors and concomitant diseases that could influence the prognosis and be significant in the treatment;</p></list-item><list-item><label>&#x02014;</label><p>identifying demonstrable causes of high blood pressure;</p></list-item><list-item><label>&#x02014;</label><p>evaluating the possible presence of organ damage and cardiovascular diseases.</p></list-item></list></p><table-wrap id="pharmaceuticals-02-00125-t001" position="float"><object-id pub-id-type="pii">pharmaceuticals-02-00125-t001_Table 1</object-id><label>Table 1</label><caption><p>Blood pressure classification in adults [<xref rid="B3-pharmaceuticals-02-00125" ref-type="bibr">3</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Blood pressure classification</th><th align="left" valign="middle" rowspan="1" colspan="1">Systolic</th><th align="left" valign="middle" rowspan="1" colspan="1">Diastolic</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">normal</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;120 mmHg</td><td align="left" valign="middle" rowspan="1" colspan="1">and &#x0003c;80 mmHg</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">prehypertension</td><td align="left" valign="middle" rowspan="1" colspan="1">120&#x02013;139 mmHg</td><td align="left" valign="middle" rowspan="1" colspan="1">or 80&#x02013;89 mmHg</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">stage 1 hypertension</td><td align="left" valign="middle" rowspan="1" colspan="1">140&#x02013;159 mmHg</td><td align="left" valign="middle" rowspan="1" colspan="1">or 90&#x02013;99 mmHg</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">stage 2 hypertension</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x02265;160 mmHg</td><td align="left" valign="middle" rowspan="1" colspan="1">or &#x02265; 100 mmHg</td></tr></tbody></table></table-wrap><p>A meta-analysis of 61 prospective, observational studies of over one million patients in total showed that there was a 7% (6.95&#x02013;7.05%) risk reduction in cardiovascular mortality for every 2 mmHg decrease in systolic blood pressure (SBP) and even a 10% (9.94&#x02013;10.06%) reduction in the risk of death from cerebro-vascular accidents (<xref ref-type="fig" rid="pharmaceuticals-02-00125-f002">Figure 2</xref>) [<xref rid="B3-pharmaceuticals-02-00125" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceuticals-02-00125" ref-type="bibr">4</xref>]. It is estimated that 370,000 coronary events in men and 150,000 coronary events in women could be prevented if blood pressure could be treated according to the blood pressure goals in the guidelines [<xref rid="B5-pharmaceuticals-02-00125" ref-type="bibr">5</xref>]. </p><fig id="pharmaceuticals-02-00125-f002" position="float"><label>Figure 2</label><caption><p>Systolic blood pressure distribution (the confidence interval were not reported, but were small given the sample size of n = 1,412, e.g., for the CVA patients respectively 4.8&#x02013;7.4, 6.7&#x02013;9.5, and 12.2&#x02013;15.8%) [<xref rid="B3-pharmaceuticals-02-00125" ref-type="bibr">3</xref>].</p></caption><graphic xlink:href="pharmaceuticals-02-00125-g002"/></fig><p>One of the most significant reasons for poor control is insufficient medical treatment to intensify antihypertensive therapy in patients unable to attain the blood pressure goals [<xref rid="B6-pharmaceuticals-02-00125" ref-type="bibr">6</xref>]. Extra attention to the promotion of compliance seems to be very important in reaching acceptable blood pressure. Medical guidance (from doctors or nurse practitioners) plays an essential role in this process, where the educational role in promoting compliance seems to be of particular importance. Psychological factors, such as lack of guilt, regret or shame, are strong determinants of lack of compliance [<xref rid="B7-pharmaceuticals-02-00125" ref-type="bibr">7</xref>]. </p><p>Various extensive studies have demonstrated that it is certainly possible to achieve blood pressure goals in patients with hypertension. However, the great majority will eventually require two or more antihypertensive agents to achieve this [<xref rid="B8-pharmaceuticals-02-00125" ref-type="bibr">8</xref>]. Both the American and the European guidelines recommend starting with two antihypertensive agents in patients with an elevated cardiovascular risk or with a blood pressure exceeding 20/10 mmHg above the target value [<xref rid="B3-pharmaceuticals-02-00125" ref-type="bibr">3</xref>]. The &#x02018;JNC 7 report&#x02019; advises the use of combinations of antihypertensive agents as initial therapy, to be administered, if indicated, in patients with stage 2 hypertension (SBP &#x02265; 160 mmHg or diastolic blood pressure (DBP) &#x02265; 100 mmHg), in particular to reach target values more rapidly, but also to avoid multiple medication &#x02018;titration&#x02019; steps and multiple patient visits. </p></sec><sec><title>2. The Combination with Olmesartan and Amlodipine (the COACH study)</title><p>Combination therapy with antihypertensive agents utilises different mechanisms of action and may be responsible for a more effective decrease in blood pressure [<xref rid="B3-pharmaceuticals-02-00125" ref-type="bibr">3</xref>]. One of the medicinal products in the combination could also possibly counteract the side effects of the other. For example, calcium antagonists are powerful, intrinsically natriuraemic, vasodilators resulting in a negative sodium balance and the stimulation of the renin-angiotensin-aldosterone system (RAAS), while angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors, in contrast, block the RAAS, and, if administered in combination with calcium antagonists, in fact enhance their antihypertensive effects. Peripheral oedema, one of the side effects of dihydropyridine calcium antagonists, probably results from preferential arteriolar vasodilation and an increase in the pressure gradient between the arterial and venous capillaries, causing an exudate of interstitial fluid [<xref rid="B9-pharmaceuticals-02-00125" ref-type="bibr">9</xref>]. This effect can be improved through concurrent administration of ARBs or ACE inhibitors, which reduce the precapillary resistance, normalise the intracapillary pressure and reduce fluid exudate [<xref rid="B3-pharmaceuticals-02-00125" ref-type="bibr">3</xref>]. In addition, suppression of the RAAS has been demonstrated to protect against target-organ damage and reduce the risk of cardiovascular disease [<xref rid="B10-pharmaceuticals-02-00125" ref-type="bibr">10</xref>].</p><p>The treatment of hypertension increasingly involves a combination of an ARB and a dihydropyridine calcium antagonist, and, in the past few years, fixed drug combinations have been used in a dose that is below the dose normally prescribed when each drug is used on its own [<xref rid="B11-pharmaceuticals-02-00125" ref-type="bibr">11</xref>]. The combination of olmesartan and amlodipine is indicated in the treatment of hypertension when initial therapy to achieve the blood pressure goals is not effective. Combination therapy has been extensively investigated in factorial design studies. These compare all monotherapy doses with all possible combinations of these dosages. This enables a good comparison to be made between the effectiveness of the combination and that of the individual monotherapy, with the latter being compared with a placebo for internal validation [<xref rid="B12-pharmaceuticals-02-00125" ref-type="bibr">12</xref>].</p><p>The purpose of the COACH study (Combination of Olmesartan Medoxomil and Amlodipine Besylate in Controlling High Blood Pressure) was to investigate the effectiveness and the safety profile of combinations of olmesartan and amlodipine (Sevikar<sup>&#x000ae;</sup>) against monotherapy in patients with mild to severe hypertension [<xref rid="B13-pharmaceuticals-02-00125" ref-type="bibr">13</xref>]. The study had a multicentre, randomised, double-blind, placebo-controlled, factorial design. </p><p>54.3% (52.1&#x02013;56.5%) of the 1,940 randomised patients were male. The average age was 54 years and 19.8% were over 65 years of age. The average blood pressure at the start of the study was 164/102 mmHg, and 79.3% of patients had stage 2 hypertension. The combination therapy with olmesartan/amlodipine produced decreases in diastolic blood pressure (from &#x02013;14.0 mmHg with olmesartan/amlodipine 20/5 mg to &#x02013;19.0 mmHg with olmesartan/amlodipine 40/10 mg) and in systolic blood pressure (from &#x02013;23.6% mmHg with olmesartan/amlodipine 20/5 mg to &#x02013;30.1 mmHg with olmesartan/amlodipine 40/10 mg; see <xref ref-type="fig" rid="pharmaceuticals-02-00125-f003">Figure 3</xref>) [<xref rid="B13-pharmaceuticals-02-00125" ref-type="bibr">13</xref>]. Incremental dosages were associated with dose-dependent decreases of blood pressure. However, the combination therapies produced better decreases than did the monotherapies (p &#x0003c; 0.001 for all equipotent dose comparisons). </p><p>The BP goals were most frequently achieved in the &#x02018;combination therapy group&#x02019;, with 56.3% (54.1&#x02013;58.5%) and 54.0% (51.8&#x02013;56.2%) of patients reaching adequate blood pressure of &#x0003c;140/90 mmHg with olmesartan/amlodipine 20/10 and 40/10 respectively. Combination therapy was generally well tolerated. The most common side effect was oedema (olmesartan 20 mg 9.9% (8.6&#x02013;11.3%), amlodipine 10 mg 36.8% (34.7&#x02013;39.0%), placebo 12.3% (10.9&#x02013;13.8%)). The frequency of oedema was lower in the groups combining amlodipine 10 mg with olmesartan 10 mg (26.5%, 24.5&#x02013;28.5%), 20 mg (25.6%, 23.7&#x02013;27.6%) or 40 mg (23.5%, 21.6&#x02013;25.4%).</p><fig id="pharmaceuticals-02-00125-f003" position="float"><label>Figure 3</label><caption><p>Effect of incremental dosages on diastolic and systolic blood pressure to week eight in 1,940 intention-to-treat patients [<xref rid="B13-pharmaceuticals-02-00125" ref-type="bibr">13</xref>]. Incremental dosages produced dose-dependent decreases of blood pressure. However, the combination therapies produced better decreases than did the monotherapies (p&#x0003c;0.001 for all equipotent dose comparisons).</p></caption><graphic xlink:href="pharmaceuticals-02-00125-g003"/></fig></sec><sec><title>3. Discussion</title><p>These findings of dose-dependent effectiveness with a combination of olmesartan and amlodipine are consistent with the results both from comparable studies of other fixed-dose combinations and from other studies specifically investigating a combination with a different ARB: valsartan with amlodipine [<xref rid="B13-pharmaceuticals-02-00125" ref-type="bibr">13</xref>].</p><p>There are a number of fixed-dose antihypertensive combinations, such as ARBs combined with a diuretic agent (hydrochlorothiazide) and ACE inhibitors combined with a diuretic or a calcium antagonist. The treatment that underlies these combinations is consistent with the JNC 7 recommendation, which stipulates that combinations should comprise of antihypertensive constituents that work through different mechanisms of action in order to achieve maximum therapeutic effect [<xref rid="B3-pharmaceuticals-02-00125" ref-type="bibr">3</xref>]. Both the European and the American guidelines for the treatment of hypertension indicate the importance of combination therapy in achieving the blood pressure goals more rapidly [<xref rid="B3-pharmaceuticals-02-00125" ref-type="bibr">3</xref>,<xref rid="B14-pharmaceuticals-02-00125" ref-type="bibr">14</xref>]. These guidelines recommend combination therapy, if indicated, as initial therapy when a reduction exceeding 20/10 mmHg is required to attain the blood pressure goals. However, the combination of olmesartan and amlodipine has not yet been authorised for initial therapy of hypertension. </p><p>Fixed-dose combinations could be regarded as more patient friendly than taking two medicinal products separately. A recent meta-analysis demonstrated that compliance with fixed-dose antihypertensive combinations was significantly better than compliance with two separate medicinal products [<xref rid="B15-pharmaceuticals-02-00125" ref-type="bibr">15</xref>]. </p><p>When a higher dose of amlodipine was combined with increasing dosages of olmesartan, the lower incidence of oedema in the COACH study was consistent with other studies, where the use of a RAAS blocker combined with amlodipine reduced the probability of amlodipine-induced oedema [<xref rid="B13-pharmaceuticals-02-00125" ref-type="bibr">13</xref>,<xref rid="B15-pharmaceuticals-02-00125" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceuticals-02-00125" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceuticals-02-00125" ref-type="bibr">17</xref>]. Another prominent finding of the COACH study is that it is one of the very few trials of antihypertensive combinations that <italic>actively</italic> investigates the development and the severity of oedema [<xref rid="B3-pharmaceuticals-02-00125" ref-type="bibr">3</xref>]. Consequently, the incidence of oedema is higher than in other studies, which only passively recorded oedema. </p><p>One study of valsartan and amlodipine, which followed a passive recording system (side effects were &#x02018;voluntarily&#x02019; reported by patients through asking general questions, or were diagnosed during physical examination), showed that 8.7% (2.1&#x02013;26.5%) of patients developed oedema while using amlodipine monotherapy and 3.0% (0&#x02013;17.2%) while using placebo [<xref rid="B17-pharmaceuticals-02-00125" ref-type="bibr">17</xref>], compared to between 13.0% (11.5&#x02013;14.5%) and 36.8% (34.7&#x02013;38.9%) while using amlodipine monotherapy and 12.3% (10.9&#x02013;14.9%) while using placebo in the COACH study [<xref rid="B13-pharmaceuticals-02-00125" ref-type="bibr">13</xref>]. In contrast, these findings were in line with those from studies of amlodipine monotherapy that included a questionnaire with very specific questions regarding oedema. Leonetti <italic>et al</italic>. reported 19% (16.3&#x02013;21.6%) peripheral oedema while using amlodipine 5 or 10 mg in a study with a specific questionnaire actively asking after these symptoms [<xref rid="B18-pharmaceuticals-02-00125" ref-type="bibr">18</xref>]. </p><p>Another study (the CASTLE study), which followed a proactive monitoring system, even showed that 22.1% (16.8&#x02013;27.0%) of patients who received amlodipine 5 or 10 mg had oedema [<xref rid="B19-pharmaceuticals-02-00125" ref-type="bibr">19</xref>]. In the VALUE study (also with an active monitoring system), 32.9% of patients using amlodipine 5 or 10 mg with or without hydrochlorothiazide had oedema [<xref rid="B20-pharmaceuticals-02-00125" ref-type="bibr">20</xref>]. Peripheral oedema while using ARBs in these studies developed in 8.9% (8.3&#x02013;9.5%) of patients using candesartan and in 14.9% (14.2&#x02013;15.6%) of patients using valsartan, which was comparable with the incidence of olmesartan in the COACH study [<xref rid="B19-pharmaceuticals-02-00125" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceuticals-02-00125" ref-type="bibr">20</xref>]. </p><p>In the last year three double blind controlled European studies including 500&#x02013;1,000 patients each and performed independently of one another have confirmed the above studies, and have demonstrated similar efficacy-safety effects from the combination of olmesartan medoxomil with amlodipine, particularly for patients not achieving adequate blood pressure control with olmesartan monotherapy [<xref rid="B21-pharmaceuticals-02-00125" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceuticals-02-00125" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceuticals-02-00125" ref-type="bibr">23</xref>]. We should add that, since hydrochlorothiazide can also be combined with olmesartan, it may worthwhile to consider here the results of the recently published ACCOMPLISH trial performed in noless than 11,506 patients with a mean follow-up of 36 months [<xref rid="B24-pharmaceuticals-02-00125" ref-type="bibr">24</xref>]. </p></sec><sec><title>4. Conclusions</title><p>In conclusion, combinations of olmesartan and amlodipine were significantly more effective at reducing blood pressure and realising guideline blood pressure goals in patients with mild to severe hypertension than monotherapy (with a placebo component). Combination therapy is well tolerated and is associated with a lower incidence of side effects, such as oedema, compared to monotherapy with high amlodipine dosages (10 mg). </p></sec></body><back><ack><title>Acknowledgements</title><p>The authors thank M. Ridderikhof, Academic Medical Centre, Amsterdam for providing a critical review of the paper. </p></ack><notes><title>Disclaimer</title><p>This article has been re-produced as a direct translation in English from its original source which was published in <italic>Cardio</italic>
<italic>Actueel</italic>
<bold>2009</bold>, (2), 1&#x02013;9 (in Dutch).</p></notes><ref-list><title>References and Notes</title><ref id="B1-pharmaceuticals-02-00125"><label>1.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ong</surname><given-names>K.L.</given-names></name><name><surname>Cheung</surname><given-names>B.M.</given-names></name><name><surname>Man</surname><given-names>Y.B.</given-names></name><name><surname>Lau</surname><given-names>C.P.</given-names></name><name><surname>Lam</surname><given-names>S.L.</given-names></name></person-group>
<article-title>Prevalence, awareness, treatment, and control of hypertension among United States adults 1999&#x02013;2004</article-title>
<source>Hypertension</source>
<year>2007</year>
<volume>49</volume>
<fpage>69</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="pmid">17159087</pub-id></element-citation></ref><ref id="B2-pharmaceuticals-02-00125"><label>2.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.R.</given-names></name><name><surname>Alexander</surname><given-names>G.C.</given-names></name><name><surname>Stafford</surname><given-names>R.S.</given-names></name></person-group>
<article-title>Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States</article-title>
<source>Arch. Intern. Med.</source>
<year>2007</year>
<volume>167</volume>
<fpage>141</fpage>
<lpage>147</lpage>
<pub-id pub-id-type="pmid">17242314</pub-id></element-citation></ref><ref id="B3-pharmaceuticals-02-00125"><label>3.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chobanian</surname><given-names>A.V.</given-names></name><name><surname>Bakris</surname><given-names>G.L.</given-names></name><name><surname>Black</surname><given-names>H.R.</given-names></name><name><surname>Cushman</surname><given-names>W.C.</given-names></name><name><surname>Green</surname><given-names>L.A.</given-names></name><name><surname>Izzo</surname><given-names>J.L.</given-names><suffix>Jr.</suffix></name><name><surname>Materson</surname><given-names>B.J.</given-names></name><name><surname>Oparil</surname><given-names>S.</given-names></name><name><surname>Wright</surname><given-names>J.T.</given-names></name><name><surname>Roccella</surname><given-names>E.J.</given-names></name></person-group>
<collab collab-type="authors">National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee</collab>
<article-title>The Seventh Report of Joint National Committee on Prevention, Detection, Evaluation. and Treatment of High Blood Pressure: The JNC 7 report</article-title>
<source>JAMA</source>
<year>2003</year>
<volume>289</volume>
<fpage>2560</fpage>
<lpage>2572</lpage>
<pub-id pub-id-type="pmid">12748199</pub-id></element-citation></ref><ref id="B4-pharmaceuticals-02-00125"><label>4.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lewington</surname><given-names>S.</given-names></name><name><surname>Clarke</surname><given-names>R.</given-names></name><name><surname>Qizilbash</surname><given-names>N.</given-names></name><name><surname>Petro</surname><given-names>R.</given-names></name><name><surname>Collins</surname><given-names>R.</given-names></name></person-group>
<collab collab-type="authors">Prospective Studies Collaboration</collab>
<article-title>Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies</article-title>
<source>Lancet</source>
<year>2002</year>
<volume>360</volume>
<fpage>1903</fpage>
<lpage>1913</lpage>
<pub-id pub-id-type="pmid">12493255</pub-id></element-citation></ref><ref id="B5-pharmaceuticals-02-00125"><label>5.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lopez</surname><given-names>V.A.</given-names></name><name><surname>Franklin</surname><given-names>S.S.</given-names></name><name><surname>Tang</surname><given-names>S.</given-names></name><name><surname>Wong</surname><given-names>N.D.</given-names></name></person-group>
<article-title>Coronary heart disease events, preventable by control of blood pressure and lipids in US adults with hypertension</article-title>
<source>J. Clin. Hypertens.</source>
<year>2007</year>
<volume>9</volume>
<fpage>436</fpage>
<lpage>443</lpage>
</element-citation></ref><ref id="B6-pharmaceuticals-02-00125"><label>6.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Okonofua</surname><given-names>E.C.</given-names></name><name><surname>Simpson</surname><given-names>K.N.</given-names></name><name><surname>Jesri</surname><given-names>A.</given-names></name><name><surname>Rehman</surname><given-names>S.U.</given-names></name><name><surname>Durkalski</surname><given-names>V.L.</given-names></name><name><surname>Egan</surname><given-names>B.M.</given-names></name></person-group>
<article-title>Therapeutic inertia is an impediment to achieving the healthy people 2010 blood pressure control goals</article-title>
<source>Hypertension</source>
<year>2006</year>
<volume>47</volume>
<fpage>345</fpage>
<lpage>351</lpage>
<pub-id pub-id-type="pmid">16432045</pub-id></element-citation></ref><ref id="B7-pharmaceuticals-02-00125"><label>7.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Okken</surname><given-names>V.S.</given-names></name><name><surname>Niemeijer</surname><given-names>M.G.</given-names></name><name><surname>Dijkstra</surname><given-names>A.</given-names></name><name><surname>Baarsman</surname><given-names>M.W.</given-names></name><name><surname>Said</surname><given-names>S.</given-names></name><name><surname>Hoogenberg</surname><given-names>K.</given-names></name><name><surname>Orfgen</surname><given-names>H.</given-names></name><name><surname>Ottens</surname><given-names>S.</given-names></name><name><surname>Cleophas</surname><given-names>T.</given-names></name></person-group>
<article-title>The effect of physical, social and psychological factors on drug compliance in patients with mild hypertension</article-title>
<source>Neth. Heart J.</source>
<year>2008</year>
<volume>16</volume>
<fpage>197</fpage>
<lpage>200</lpage>
<pub-id pub-id-type="pmid">18665204</pub-id></element-citation></ref><ref id="B8-pharmaceuticals-02-00125"><label>8.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>D&#x000e4;hlof</surname><given-names>B.</given-names></name><name><surname>Sever</surname><given-names>P.S.</given-names></name><name><surname>Poulter</surname><given-names>N.R.</given-names></name><name><surname>Wedel</surname><given-names>H.</given-names></name><name><surname>Gareth Weevers</surname><given-names>D.</given-names></name><name><surname>Caulfield</surname><given-names>M.</given-names></name><name><surname>Collins</surname><given-names>R.</given-names></name><name><surname>Kjeldsen</surname><given-names>S.E.</given-names></name><name><surname>Kristinsson</surname><given-names>A.</given-names></name><name><surname>McInnes</surname><given-names>G.</given-names></name><name><surname>Mehlsen</surname><given-names>J.</given-names></name><name><surname>Miettinen</surname><given-names>M.</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>E.</given-names></name><name><surname>Ostergren</surname><given-names>J.</given-names></name></person-group>
<collab collab-type="authors">ASCOT Investigators</collab>
<article-title>Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendrolumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial- Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomized controlled trial</article-title>
<source>Lancet</source>
<year>2005</year>
<volume>366</volume>
<fpage>895</fpage>
<lpage>906</lpage>
<pub-id pub-id-type="pmid">16154016</pub-id></element-citation></ref><ref id="B9-pharmaceuticals-02-00125"><label>9.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pedrinelli</surname><given-names>R.</given-names></name><name><surname>Dell&#x02019;Omo</surname><given-names>G.</given-names></name><name><surname>Mariani</surname><given-names>M.</given-names></name></person-group>
<article-title>Calcium channel blockers, postural vasoconstriction and dependent oedema in essential hypertension</article-title>
<source>J. Hum. Hypertens.</source>
<year>2001</year>
<volume>15</volume>
<fpage>455</fpage>
<lpage>461</lpage>
<pub-id pub-id-type="pmid">11464254</pub-id></element-citation></ref><ref id="B10-pharmaceuticals-02-00125"><label>10.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hollenberg</surname><given-names>N.K.</given-names></name></person-group>
<article-title>The renin-angiotensin system and cardiovascular disease</article-title>
<source>Blood Press. Suppl.</source>
<year>2000</year>
<volume>1</volume>
<fpage>5</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">11059628</pub-id></element-citation></ref><ref id="B11-pharmaceuticals-02-00125"><label>11.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chalmers</surname><given-names>J.</given-names></name></person-group>
<article-title>The use of free and fixed drug combinations to improve hypertension control in our populations</article-title>
<source>Eur. Heart. J.</source>
<year>1999</year>
<volume>20</volume>
<fpage>1060</fpage>
<lpage>1061</lpage>
<pub-id pub-id-type="pmid">10413632</pub-id></element-citation></ref><ref id="B12-pharmaceuticals-02-00125"><label>12.</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Chow</surname><given-names>S.C.</given-names></name><name><surname>Liu</surname><given-names>J.P.</given-names></name></person-group>
<article-title>Combination trials</article-title>
<source>Design and Analysis of Clinical Trials: Concepts and Methodologies</source>
<edition>2nd</edition>
<publisher-name>Wiley</publisher-name>
<publisher-loc>Hoboken, USA</publisher-loc>
<year>2004</year>
<fpage>270</fpage>
<lpage>283</lpage>
</element-citation></ref><ref id="B13-pharmaceuticals-02-00125"><label>13.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chrysant</surname><given-names>S.G.</given-names></name><name><surname>Melino</surname><given-names>M.</given-names></name><name><surname>Karki</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Heyrman</surname><given-names>R.</given-names></name></person-group>
<article-title>The combination of olmesartan medoximil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study</article-title>
<source>Clin. Ther.</source>
<year>2008</year>
<volume>30</volume>
<fpage>587</fpage>
<lpage>604</lpage>
<pub-id pub-id-type="pmid">18498909</pub-id></element-citation></ref><ref id="B14-pharmaceuticals-02-00125"><label>14.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mancia</surname><given-names>G.</given-names></name><name><surname>De Backer</surname><given-names>G.</given-names></name><name><surname>Dominiczak</surname><given-names>A.</given-names></name><name><surname>Lifkova</surname><given-names>R.</given-names></name><name><surname>Fagard</surname><given-names>R.</given-names></name><name><surname>Germano</surname><given-names>G.</given-names></name><name><surname>Grassi</surname><given-names>G.</given-names></name><name><surname>Heagerty</surname><given-names>A.</given-names></name><name><surname>Kjeldsen</surname><given-names>S.</given-names></name><name><surname>Laurent</surname><given-names>S.</given-names></name><name><surname>Nakiewicz</surname><given-names>K.</given-names></name><name><surname>Ruilope</surname><given-names>L.</given-names></name><name><surname>Rynkiewicz</surname><given-names>A.</given-names></name><name><surname>Schmieder</surname><given-names>R.</given-names></name><name><surname>Struijker Boudier</surname><given-names>H.</given-names></name><name><surname>Zanchetti</surname><given-names>A.</given-names></name><name><surname>Vahanian</surname><given-names>A.</given-names></name><name><surname>Camm</surname><given-names>J.</given-names></name><name><surname>De Laterina</surname><given-names>R.</given-names></name><name><surname>Dean</surname><given-names>V.</given-names></name><name><surname>Dickstein</surname><given-names>K.</given-names></name><name><surname>Filippatos</surname><given-names>G.</given-names></name><name><surname>Funck-Brentano</surname><given-names>C.</given-names></name><name><surname>Hellemans</surname><given-names>I.</given-names></name><name><surname>Kristensen</surname><given-names>S.</given-names></name><name><surname>McGregor</surname><given-names>K.</given-names></name><name><surname>Sechten</surname><given-names>U.</given-names></name><name><surname>Silber</surname><given-names>S.</given-names></name><name><surname>Tendera</surname><given-names>M.</given-names></name><name><surname>Widinsky</surname><given-names>P.</given-names></name><name><surname>Zamorano</surname><given-names>J.</given-names></name><name><surname>Erdine</surname><given-names>S.</given-names></name><name><surname>Kiowski</surname><given-names>W.</given-names></name><name><surname>Agabiti</surname><given-names>E.</given-names></name><name><surname>Ambrosioni</surname><given-names>E.</given-names></name><name><surname>Lindholm</surname><given-names>L.</given-names></name><name><surname>Manolis</surname><given-names>A.</given-names></name><name><surname>Nilsson</surname><given-names>P.</given-names></name><name><surname>Redon</surname><given-names>J.</given-names></name><name><surname>Viigimaa</surname><given-names>M.</given-names></name><name><surname>Adamopoulos</surname><given-names>G.</given-names></name><name><surname>Bertoneu</surname><given-names>V.</given-names></name><name><surname>Clement</surname><given-names>D.</given-names></name><name><surname>Ruschitzka</surname><given-names>F.</given-names></name><name><surname>Famargo</surname><given-names>J.</given-names></name><name><surname>Van Zwieten</surname><given-names>P.</given-names></name><name><surname>Waeber</surname><given-names>B.</given-names></name><name><surname>Williams</surname><given-names>B.</given-names></name><name><surname>Zumorano</surname><given-names>J.L.</given-names></name></person-group>
<article-title>The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension</article-title>
<source> Eur. Heart J.</source>
<year>2007</year>
<volume>28</volume>
<fpage>1462</fpage>
<lpage>1536</lpage>
<pub-id pub-id-type="pmid">17562668</pub-id></element-citation></ref><ref id="B15-pharmaceuticals-02-00125"><label>15.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bangalore</surname><given-names>S.</given-names></name><name><surname>Kamalakkannan</surname><given-names>G.</given-names></name><name><surname>Parkar</surname><given-names>S.</given-names></name><name><surname>Messerli</surname><given-names>F.H.</given-names></name></person-group>
<article-title>Fixed-dose combinations improve medication compliance: A meta-analysis</article-title>
<source>Am. J. Med.</source>
<year>2007</year>
<volume>120</volume>
<fpage>713</fpage>
<lpage>719</lpage>
<pub-id pub-id-type="pmid">17679131</pub-id></element-citation></ref><ref id="B16-pharmaceuticals-02-00125"><label>16.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Philipp</surname><given-names>T.</given-names></name><name><surname>Smith</surname><given-names>T.R.</given-names></name><name><surname>Glazer</surname><given-names>R.</given-names></name><name><surname>Wensing</surname><given-names>M.</given-names></name><name><surname>Yen</surname><given-names>J.</given-names></name><name><surname>Jin</surname><given-names>J.</given-names></name><name><surname>Scheider</surname><given-names>H.</given-names></name><name><surname>Pospiech</surname><given-names>R.</given-names></name></person-group>
<article-title>Two multicenter, 8 week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and the tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension</article-title>
<source>Clin. Ther.</source>
<year>2007</year>
<volume>29</volume>
<fpage>563</fpage>
<lpage>580</lpage>
<pub-id pub-id-type="pmid">17617280</pub-id></element-citation></ref><ref id="B17-pharmaceuticals-02-00125"><label>17.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fogari</surname><given-names>R.</given-names></name><name><surname>Zoppi</surname><given-names>A.</given-names></name><name><surname>Derosa</surname><given-names>G.</given-names></name><name><surname>Mugekini</surname><given-names>A.</given-names></name><name><surname>Lazzaro</surname><given-names>P.</given-names></name><name><surname>Rinaldi</surname><given-names>A.</given-names></name><name><surname>Fogari</surname><given-names>E.</given-names></name><name><surname>Preti</surname><given-names>P.</given-names></name></person-group>
<article-title>Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients</article-title>
<source>J. Hum. Hypertens.</source>
<year>2007</year>
<volume>21</volume>
<fpage>220</fpage>
<lpage>224</lpage>
<pub-id pub-id-type="pmid">17215848</pub-id></element-citation></ref><ref id="B18-pharmaceuticals-02-00125"><label>18.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leonetti</surname><given-names>G.</given-names></name><name><surname>Magnani</surname><given-names>B.</given-names></name><name><surname>Pessina</surname><given-names>A.C.</given-names></name><name><surname>Rappelli</surname><given-names> A.</given-names></name><name><surname>Trimarco</surname><given-names>B.</given-names></name><name><surname>Zanchetti</surname><given-names>A.</given-names></name></person-group>
<article-title>Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertension</article-title>
<source>Am. J. Hypertens.</source>
<year>2002</year>
<volume>15</volume>
<fpage>932</fpage>
<lpage>940</lpage>
<pub-id pub-id-type="pmid">12441211</pub-id></element-citation></ref><ref id="B19-pharmaceuticals-02-00125"><label>19.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kloner</surname><given-names>R.A.</given-names></name><name><surname>Weinberger</surname><given-names>M.</given-names></name><name><surname>Pool</surname><given-names>J.L.</given-names></name><name><surname>Chrysant</surname><given-names>S.</given-names></name><name><surname>Prasad</surname><given-names>R.</given-names></name><name><surname>Harris</surname><given-names>S.</given-names></name><name><surname>Zyczynski</surname><given-names>I.</given-names></name><name><surname>Leidy</surname><given-names>N.</given-names></name><name><surname>Nichelson</surname><given-names>E.</given-names></name></person-group>
<article-title>Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) study investigators. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension</article-title>
<source> Am. J. Cardiol.</source>
<year>2001</year>
<volume>87</volume>
<fpage>727</fpage>
<lpage>731</lpage>
<pub-id pub-id-type="pmid">11249891</pub-id></element-citation></ref><ref id="B20-pharmaceuticals-02-00125"><label>20.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Julius</surname><given-names>S.</given-names></name><name><surname>Kjeldsen</surname><given-names>S.E.</given-names></name><name><surname>Weber</surname><given-names>M.</given-names></name><name><surname>Ekman</surname><given-names>S.</given-names></name><name><surname>Hansson</surname><given-names>L.</given-names></name><name><surname>Hua</surname><given-names>T.</given-names></name><name><surname>Laragh</surname><given-names>J.</given-names></name><name><surname>McInnes</surname><given-names>G.</given-names></name><name><surname>Mitchell</surname><given-names>L.</given-names></name><name><surname>Plat</surname><given-names>F.</given-names></name><name><surname>Schork</surname><given-names>A.</given-names></name><name><surname>Smith</surname><given-names>B.</given-names></name><name><surname>Zanchetti</surname><given-names>A.</given-names></name></person-group>
<collab collab-type="authors">VALUE Trial Group</collab>
<article-title>Outcomes in hypertensive patients at high cardiovascular risk treatment with regimens based on valsartan or amlodipine. The VALUE randomized trial</article-title>
<source>Lancet</source>
<year>2004</year>
<volume>363</volume>
<fpage>2022</fpage>
<lpage>2031</lpage>
<pub-id pub-id-type="pmid">15207952</pub-id></element-citation></ref><ref id="B21-pharmaceuticals-02-00125"><label>21.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Volpe</surname><given-names>M.</given-names></name><name><surname>Brommer</surname><given-names>P.</given-names></name><name><surname>Haag</surname><given-names>U.</given-names></name><name><surname>Miele</surname><given-names>C.</given-names></name></person-group>
<article-title>Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: A randomized double blind parallel group multicenter trial</article-title>
<source>Clin. Drug Invest.</source>
<year>2009</year>
<volume>29</volume>
<fpage>11</fpage>
<lpage>25</lpage>
</element-citation></ref><ref id="B22-pharmaceuticals-02-00125"><label>22.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mourad</surname><given-names>J.</given-names></name><name><surname>Le Jeune</surname><given-names>S.</given-names></name></person-group>
<article-title>Effective systolic blood pressure reduction with olmesartan medoxomil/amlodipine combination therapy: post hoc analysis of data from a randomized double blind parallel group multicenter study</article-title>
<source>Clin. Drug Invest.</source>
<year>2009</year>
<volume>29</volume>
<fpage>419</fpage>
<lpage>425</lpage>
<pub-id pub-id-type="doi">10.2165/00044011-200929060-00005</pub-id>
</element-citation></ref><ref id="B23-pharmaceuticals-02-00125"><label>23.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barrios</surname><given-names>V.</given-names></name><name><surname>Brommer</surname><given-names>P.</given-names></name><name><surname>Haag</surname><given-names>U.</given-names></name><name><surname>Calderon</surname><given-names>A.</given-names></name><name><surname>Escobar</surname><given-names>C.</given-names></name></person-group>
<article-title>Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate to severe hypertension after monotherapy: a randomized double blind multicenter study</article-title>
<source>Clin. Drug Invest.</source>
<year>2009</year>
<volume>29</volume>
<fpage>427</fpage>
<lpage>439</lpage>
</element-citation></ref><ref id="B24-pharmaceuticals-02-00125"><label>24.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jamerson</surname><given-names>K.</given-names></name><name><surname>Weber</surname><given-names>M.A.</given-names></name><name><surname>Bakris</surname><given-names>G.L.</given-names></name><name><surname>Dahlof</surname><given-names>B.</given-names></name><name><surname>Pitt</surname><given-names>B.</given-names></name><name><surname>Shi</surname><given-names>V.</given-names></name><name><surname>Heaster</surname><given-names>A.</given-names></name><name><surname>Gupte</surname><given-names>J.</given-names></name><name><surname>Gatlin</surname><given-names>M.</given-names></name><name><surname>Velazquez</surname><given-names>E.</given-names></name></person-group>
<article-title>Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients</article-title>
<source>N. Engl. J. Med.</source>
<year>2008</year>
<volume>359</volume>
<fpage>2417</fpage>
<lpage>2428</lpage>
<pub-id pub-id-type="pmid">19052124</pub-id></element-citation></ref></ref-list></back></article>